Using our insurer’s formulary as an example, ... have a lower average wholesale price. 13 The LAMA/LABA inhaler and ICS inhaler combination would also simplify future step-down to dual ...

A Comparison: LABA/ICS vs LABA/LAMA. In a 52-week trial, 3360 patients with moderate-to-severe COPD received either the twice-daily fixed-dose combination of salmeterol and fluticasone or the once ...

Recently, new fixed combinations of a LABA and a LAMA have become available. Two replicated phase 3 trials of one such combination have been performed and reported.

Long-acting beta2-agonist (LABA) in combination with a long-acting muscarinic agonist (LAMA) as effective as LABA plus inhaled corticosteroid (ICS), as measured by COPD exacerbation rates.

GlaxoSmithKline's experimental once-daily lung drug LAMA/LABA showed positive results on Monday from late stage trials in patients with chronic obstructive pulmonary disease (COPD). The Phase III ...

6 August2012, USA California (Acedrugstore.com): An experimental and novel lung medication with is a combination drug of LAMA/LABA and produced by GlaxoSmithKline and Theravance pharmaceutical compani ...

There are currently a number of LABA/LAMA fixed-dose combinations in development for COPD. 28 QVA149 (an inhaled fixed-dose combination comprising two 24-hr agents, the LABA indacaterol and the ...

Using a LABA in combination with a LAMA rather than an inhaled corticosteroid to treat COPD is more effective in preventing exacerbations, claim researchers. Patients receiving a combination of ...

LONDON (Reuters) - GlaxoSmithKline has completed final stage testing of its experimental once-daily lung disease drug LAMA/LABA and will press ahead with plans to file for approval of the medicine ...

An inhaler combining a long-acting muscarinic antagonist (LAMA) with a long-acting beta 2-agonist (LABA) has been FDA-approved for maintenance treatment of airflow obstruction in patients with ...

UMEC/VI includes two bronchodilator molecules – GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta 2 agonist (LABA ...

GlaxoSmithKline has completed final stage testing of its experimental once-daily lung disease drug LAMA/LABA and will press ahead with plans to file for approval of the medicine in global markets ...